Lupus (SLE): vizsgálatok itt: Németország
38 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- Where
- Bad Abbach, Hamburg, Mainz, München
- Életkor
- 18 év to 70 év
- People
- 245 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07430306 - 3. fázisTaking peopleRollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
- Where
- Berlin, Dresden, Essen, Freiburg im Breisgau, Hanover, Kiel, Mainz, Marburg, Münster, Regensburg, Tübingen, Wuppertal
- Életkor
- 5 év to 80 év
- People
- 1072 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07691970 - 3. fázisTaking peoplePhase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
- Where
- Berlin, Cologne, Freiburg im Breisgau, Herne, Leipzig, Mainz
- Életkor
- 12 év to 100 év
- People
- 550 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06133972 · EU 2023-505929-14-00 - 1. fázisTaking peopleTo Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
- Where
- Mainz, Munich
- Életkor
- 18 év to 75 év
- People
- 46 worldwide
- Run by
- Genentech, Inc.
See details and how to joinNCT07629583 · EU 2025-522904-26-00 - 3. fázisTaking peopleA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
- Where
- Berlin, Buxtehude, Dresden, Erlangen, Mainz, Oberhausen
- Életkor
- 18 év to 75 év
- People
- 202 worldwide
- Run by
- EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07332481 · EU 2025-523871-44-00 - 3. fázisTaking peopleA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
- Where
- Aachen, Dortmund, Hannover, Leipzig, Oldenburg, Tuebingen, Wuppertal
- Életkor
- 18 év to 75 év
- People
- 202 worldwide
- Run by
- EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07355218 · EU 2025-524855-30-00 - 3. fázisTaking peopleA Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
- Where
- Dresden, Heidelberg, Leipzig, Meerbusch, Munich
- Életkor
- 18 év to 75 év
- People
- 600 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07438496 · EU 2025-523552-31-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Where
- Berlin, Cologne, Dresden, Freiburg im Breisgau, Gommern, Greifswald, Herne, Jena, Leipzig, Mainz, Munich, Tuebingen
- Életkor
- 16 év and over
- People
- 450 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT06617325 · EU 2023-508191-11-00 - No phaseTaking peopleA Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- Where
- Kiel, Mainz
- Életkor
- 16 év and over
- People
- 223 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07175285 - 1. fázisTaking peopleStudy Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
- Where
- Bonn, Jena, Mainz, Muenster, Munich
- Életkor
- 18 év to 65 év
- People
- 48 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07201558 · EU 2025-522273-10-00 - 2. fázisTaking peopleA Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
- Where
- Bad Doberan, Minden, Munich
- Életkor
- 18 év to 74 év
- People
- 405 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07409181 · EU 2025-523488-39-00 - 1. fázisTaking peopleDose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
- Where
- Mainz, Regensburg
- Életkor
- 18 év to 60 év
- People
- 90 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06975787 · EU 2024-518288-37-00 - 3. fázisNot yet taking people in NémetországRollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Benefited from Continued Treatment.
- Where
- Berlin, Dresden, Kiel, Mainz, Marburg, Muenster, Regensburg, Tuebingen, Wuppertal
- People
- 340 worldwide
- Run by
- AstraZeneca AB
See details and how to join2026-526419-13-00 · EU 2026-526419-13-00 - 1. fázisTaking peopleA Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
- Where
- Heidelberg
- Életkor
- 18 év to 70 év
- People
- 24 worldwide
- Run by
- Cullinan Therapeutics Inc.
See details and how to joinNCT06613360 · EU 2024-518780-36-00 - 1. fázisTaking peopleA Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Where
- Augsburg, Cologne, Hanover, Mainz
- Életkor
- 18 év to 70 év
- People
- 80 worldwide
- Run by
- CRISPR Therapeutics
See details and how to joinNCT06925542 - 1. fázisTaking peopleA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
- Where
- Cologne, Erlangen, Magdeburg
- Életkor
- 18 év to 70 év
- People
- 72 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06916806 · EU 2024-519015-34-00 - 3. fázisCsak meghívásosA Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
- Where
- Berlin, Cologne, Dresden, Freiburg im Breisgau, Gommern, Herne, Jena, Leipzig, Mainz, Munich, Tuebingen
- Életkor
- 16 év and over
- People
- 760 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT04976322 · EU 2023-506368-14-00 - 1. fázisNot yet taking people in NémetországA Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
- Where
- Berlin, Erlangen, Magdeburg, Würzburg
- Életkor
- 18 év and over
- People
- 60 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07873931 - 1. fázisNot yet taking people in NémetországA study to learn how dapirolizumab pegol transfers to babies from pregnant mothers with active systemic lupus erythematosus
- Where
- Munich
- Életkor
- Up to 64 év
- People
- 10 worldwide
- Run by
- UCB Biopharma
See details and how to join2025-524595-37-00 · EU 2025-524595-37-00 - 3. fázisCsak meghívásosA Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
- Where
- Cologne, Mainz
- Életkor
- 18 év and over
- People
- 864 worldwide
- Run by
- Biogen
See details and how to joinNCT05352919 · EU 2023-505635-13-00 - 2. fázisTaking peopleA Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
- Where
- Cologne, Düsseldorf, Leipzig, München
- Életkor
- 18 év to 75 év
- People
- 220 worldwide
- Run by
- Amgen
See details and how to joinNCT06570798 - 2. fázisTaking peopleA Phase II, Open-Label, Single-Center, Single-Arm Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Blinatumomab for Treatment of Patients with Autoimmune B-Cell driven Diseases including Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc) and Granulomatous Polyangiitis (GPA), BlinA-B trial
- Where
- Leipzig
- Életkor
- 18 év and over
- People
- 5
- Run by
- Universitaet Leipzig
See details and how to join2025-523061-22-00 · EU 2025-523061-22-00 - 3. fázisTaking peopleA Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- Where
- Bad Abbach, Bad Bramstedt, Mainz, Munich
- Életkor
- 18 év and over
- People
- 113 worldwide
- Run by
- AstraZeneca AB
See details and how to join2025-523670-17-00 · EU 2025-523670-17-00 - 3. fázisTaking peopleAn Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
- Where
- Berlin, Freiburg im Breisgau, Sankt Augustin
- Életkor
- 5 év to 17 év
- People
- 100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05835310 · EU 2022-502289-25-00 - 3. fázisTaking peopleEfficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-1)
- Where
- Chemnitz, Cologne, Dresden, Erlangen, Lübeck, Munich, Planegg, Tuebingen
- Életkor
- 18 év and over
- People
- 147 worldwide
- Run by
- Bristol-Myers Squibb Services Unlimited Company
See details and how to join2022-500699-76-00 · EU 2022-500699-76-00